CO6311004A2 - Anticuerpos para el factor estimulante de colonias de granulocitos macrofagos que tienen determinantes de especificidad de union minima esencial para cdr3 especifico - Google Patents
Anticuerpos para el factor estimulante de colonias de granulocitos macrofagos que tienen determinantes de especificidad de union minima esencial para cdr3 especificoInfo
- Publication number
- CO6311004A2 CO6311004A2 CO10148019A CO10148019A CO6311004A2 CO 6311004 A2 CO6311004 A2 CO 6311004A2 CO 10148019 A CO10148019 A CO 10148019A CO 10148019 A CO10148019 A CO 10148019A CO 6311004 A2 CO6311004 A2 CO 6311004A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- stimulating factor
- macrofago
- granulocits
- determinants
- Prior art date
Links
- 230000004936 stimulating effect Effects 0.000 title 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4852208P | 2008-04-28 | 2008-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6311004A2 true CO6311004A2 (es) | 2011-08-22 |
Family
ID=41255734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10148019A CO6311004A2 (es) | 2008-04-28 | 2010-11-25 | Anticuerpos para el factor estimulante de colonias de granulocitos macrofagos que tienen determinantes de especificidad de union minima esencial para cdr3 especifico |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8168183B2 (enExample) |
| EP (2) | EP2280732B1 (enExample) |
| JP (1) | JP5688363B2 (enExample) |
| KR (2) | KR101852915B1 (enExample) |
| CN (1) | CN102037016B (enExample) |
| AU (1) | AU2009243184B2 (enExample) |
| BR (1) | BRPI0911902A2 (enExample) |
| CA (1) | CA2722137C (enExample) |
| CO (1) | CO6311004A2 (enExample) |
| DK (1) | DK2280732T3 (enExample) |
| EA (1) | EA201001691A1 (enExample) |
| ES (1) | ES2704835T3 (enExample) |
| IL (1) | IL208980A (enExample) |
| MX (1) | MX2010011761A (enExample) |
| NZ (1) | NZ588850A (enExample) |
| WO (1) | WO2009134805A2 (enExample) |
| ZA (1) | ZA201008028B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2661848C (en) | 2006-09-01 | 2015-02-03 | Therapeutic Human Polyclonals, Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| EA201001691A1 (ru) | 2008-04-28 | 2011-10-31 | Калобайос Фармасьютикалз, Инк. | Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору |
| AU2009329814B2 (en) | 2008-12-22 | 2015-06-18 | The University Of Melbourne | Osteoarthritis treatment |
| WO2010071923A1 (en) | 2008-12-22 | 2010-07-01 | The University Of Melbourne | Pain treatment |
| US8512950B2 (en) | 2010-07-21 | 2013-08-20 | Saint Louis University | Biolayer interferometry measurement of biological targets |
| RU2013156435A (ru) | 2011-07-06 | 2015-08-20 | МорфоСис АГ | Терапевтические комбинации анти-cd20 и анти-gm-csf антител и их применения |
| US9400600B2 (en) * | 2011-12-16 | 2016-07-26 | Samsung Electronics Co., Ltd. | Method, apparatus, and graphical user interface for providing visual effects on a touchscreen display |
| WO2013090989A1 (en) | 2011-12-22 | 2013-06-27 | Csl Limited | Method of treating inflammatory bowel disease |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| JP6339578B2 (ja) | 2012-10-31 | 2018-06-06 | タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ | Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤 |
| CN105705518A (zh) * | 2013-08-30 | 2016-06-22 | 塔科达有限责任公司 | 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体 |
| EP3139960B1 (en) | 2014-05-07 | 2024-01-17 | Takeda Pharmaceutical Company Limited | Liquid formulation comprising gm-csf neutralizing compound |
| CN113862300A (zh) * | 2015-10-29 | 2021-12-31 | 豪夫迈·罗氏有限公司 | 具有共同轻链的转基因兔 |
| US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
| US10870703B2 (en) * | 2017-10-02 | 2020-12-22 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist |
| JP2022517461A (ja) * | 2018-09-10 | 2022-03-09 | ヒューマニゲン インコーポレイティッド | Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法 |
| US20220040229A1 (en) | 2018-10-31 | 2022-02-10 | Humanigen, Inc. | Materials and methods for treating cancer |
| US20220395532A1 (en) | 2019-11-08 | 2022-12-15 | Humanigen, Inc. | Epha3 directed car-t cells for treatment of tumors |
| CN118561999B (zh) * | 2024-06-26 | 2025-03-14 | 武汉爱博泰克生物科技有限公司 | 抗人粒细胞-巨噬细胞集落刺激因子抗体、抗体对及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US7381801B2 (en) | 2002-02-13 | 2008-06-03 | Ludwig Institute For Cancer Research | Chimerized GM-CSF antibodies |
| AU2003244817B2 (en) * | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| AU2004205684A1 (en) * | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| GB0303337D0 (en) * | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| AU2005207003C1 (en) | 2004-01-20 | 2013-06-13 | Humanigen, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| AU2005306502B2 (en) * | 2004-11-16 | 2012-11-15 | Humanigen, Inc. | Immunoglobulin variable region cassette exchange |
| US7381802B2 (en) * | 2005-04-15 | 2008-06-03 | Universidad Nacional Autónoma De México (UNAM) | Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom |
| UA94403C2 (ru) * | 2005-04-18 | 2011-05-10 | Микромет Аг | Человеческое моноклональное антитело, которое нейтрализует gm-csf |
| SI3620171T1 (sl) * | 2005-05-18 | 2022-09-30 | Morphosys Ag | Protitelesa proti GM-CSF in uporabe zanje |
| US8211648B2 (en) | 2005-07-22 | 2012-07-03 | Kalobios Pharmaceuticals, Inc. | Secretion of antibodies without signal peptides from bacteria |
| KR20080068004A (ko) * | 2005-08-15 | 2008-07-22 | 아라나 테라퓨틱스 리미티드 | 뉴 월드 영장류 구조형성영역을 가진 조작 항체 |
| WO2007092939A2 (en) * | 2006-02-08 | 2007-08-16 | Morphotek, Inc. | Antigenic gm-csf peptides and antibodies to gm-csf |
| US8398972B2 (en) * | 2006-11-21 | 2013-03-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a GM-CSF antagonist |
| EP2402013A1 (en) * | 2006-11-21 | 2012-01-04 | Kalobios Pharmaceuticals, Inc. | Methods of Treating Chronic Inflammatory Diseases using a GM-CSF Antagonist |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| US8075885B2 (en) * | 2008-04-07 | 2011-12-13 | Kalobios Pharmaceuticals, Inc. | Methods of treating heart failure using an anti-GM-CSF antibody |
| EA201001691A1 (ru) | 2008-04-28 | 2011-10-31 | Калобайос Фармасьютикалз, Инк. | Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору |
-
2009
- 2009-04-28 EA EA201001691A patent/EA201001691A1/ru unknown
- 2009-04-28 CA CA2722137A patent/CA2722137C/en active Active
- 2009-04-28 WO PCT/US2009/041981 patent/WO2009134805A2/en not_active Ceased
- 2009-04-28 BR BRPI0911902A patent/BRPI0911902A2/pt not_active IP Right Cessation
- 2009-04-28 EP EP09739607.1A patent/EP2280732B1/en active Active
- 2009-04-28 JP JP2011507586A patent/JP5688363B2/ja active Active
- 2009-04-28 AU AU2009243184A patent/AU2009243184B2/en active Active
- 2009-04-28 DK DK09739607.1T patent/DK2280732T3/en active
- 2009-04-28 CN CN200980118423.0A patent/CN102037016B/zh active Active
- 2009-04-28 KR KR1020177023943A patent/KR101852915B1/ko active Active
- 2009-04-28 ES ES09739607T patent/ES2704835T3/es active Active
- 2009-04-28 EP EP18200356.6A patent/EP3449941A1/en not_active Ceased
- 2009-04-28 MX MX2010011761A patent/MX2010011761A/es active IP Right Grant
- 2009-04-28 KR KR1020107026423A patent/KR101824512B1/ko active Active
- 2009-04-28 US US12/431,661 patent/US8168183B2/en active Active
- 2009-04-28 NZ NZ588850A patent/NZ588850A/xx not_active IP Right Cessation
-
2010
- 2010-10-28 IL IL208980A patent/IL208980A/en active IP Right Grant
- 2010-11-09 ZA ZA2010/08028A patent/ZA201008028B/en unknown
- 2010-11-25 CO CO10148019A patent/CO6311004A2/es not_active Application Discontinuation
-
2012
- 2012-04-30 US US13/460,151 patent/US9017674B2/en active Active
-
2015
- 2015-04-02 US US14/677,604 patent/US20150344565A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL208980A (en) | 2015-06-30 |
| EP3449941A1 (en) | 2019-03-06 |
| NZ588850A (en) | 2012-12-21 |
| EA201001691A1 (ru) | 2011-10-31 |
| CN102037016A (zh) | 2011-04-27 |
| AU2009243184A1 (en) | 2009-11-05 |
| WO2009134805A3 (en) | 2010-06-03 |
| EP2280732A2 (en) | 2011-02-09 |
| US20120213776A1 (en) | 2012-08-23 |
| MX2010011761A (es) | 2010-11-30 |
| KR101824512B1 (ko) | 2018-02-02 |
| CN102037016B (zh) | 2015-06-03 |
| US20090274706A1 (en) | 2009-11-05 |
| US8168183B2 (en) | 2012-05-01 |
| KR20170126458A (ko) | 2017-11-17 |
| AU2009243184B2 (en) | 2015-06-04 |
| KR20110011638A (ko) | 2011-02-08 |
| ES2704835T3 (es) | 2019-03-20 |
| CA2722137A1 (en) | 2009-11-05 |
| WO2009134805A2 (en) | 2009-11-05 |
| JP5688363B2 (ja) | 2015-03-25 |
| EP2280732A4 (en) | 2012-11-14 |
| KR101852915B1 (ko) | 2018-04-27 |
| US9017674B2 (en) | 2015-04-28 |
| CA2722137C (en) | 2019-03-19 |
| BRPI0911902A2 (pt) | 2015-10-13 |
| DK2280732T3 (en) | 2019-01-28 |
| US20150344565A1 (en) | 2015-12-03 |
| JP2011518886A (ja) | 2011-06-30 |
| IL208980A0 (en) | 2011-01-31 |
| EP2280732B1 (en) | 2018-10-17 |
| ZA201008028B (en) | 2012-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6311004A2 (es) | Anticuerpos para el factor estimulante de colonias de granulocitos macrofagos que tienen determinantes de especificidad de union minima esencial para cdr3 especifico | |
| CY1122628T1 (el) | Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας | |
| MY157473A (en) | Antibody molecules having specificity for human ox40 | |
| TN2014000206A1 (en) | Antibody molecules having specificity for human ox40 | |
| EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
| CY1120807T1 (el) | Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συναρμογης σε ενα υποκειμενο | |
| CY1121065T1 (el) | Αναστολεις ιβατ για την αγωγη ηπατικων νοσων | |
| CY1119596T1 (el) | Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης | |
| CY1117869T1 (el) | Φαρμακοτεχνικες μορφες για απο του στοματος απελευθερωση προσροφητικων στο εντερο | |
| MX2018009945A (es) | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. | |
| CY1118530T1 (el) | Glyx-13 για χρηση σε μεθοδο θεραπευτικης αγωγης ανθεκτικης σε θεραπεια καταθλιψης | |
| IN2014DN07149A (enExample) | ||
| EA201491358A1 (ru) | Вводимые перорально кортикостероидные композиции | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| MY160687A (en) | Oral care product and methods of use and manufacture thereof | |
| BR112014031394A2 (pt) | composições e métodos para absorção transmucosa | |
| IN2012DN06309A (enExample) | ||
| EA201101303A1 (ru) | Молекулы антител, обладающие связывающей специфичностью в отношении il-13 человека | |
| EA201171043A1 (ru) | Композиции и способы длительной терапии с применением аминопиридинов | |
| UA107204C2 (uk) | Протигрибкова композиція, що містить грибковий організм pythium oligandrum | |
| PH12016500578A1 (en) | Treatment for neoplastic diseases | |
| NZ610464A (en) | Antigen binding proteins to oncostatin m (osm) | |
| BR112014023496A2 (pt) | mutantes c-raf que conferem resistência a inibidores de raf | |
| MX2013010367A (es) | Composiciones y metodos para la terapia y diagnostico de influenza. | |
| EA201500765A1 (ru) | Способы лечения сердечно-сосудистых заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |